Information and interesting ideas

Topics posted here will be in the realm of bioanalysis and biomarkers as part of new therapeutic development, with the occasional post of scientific topics that I find interesting.

Monday, March 6, 2023

AAPS Webinar: Development and Regulatory Landscape of Cell-based and CAR-T Therapies

 Tuesday May 9, 2023 @ 12:30 PM EDT

Register here.

Description

The webinar on CAR-T and cell-based therapies will touch on emerging concepts in the R&D, manufacturing and regulatory landscape of these immunotherapies. As living drugs, CAR-T and other cell-based therapies present particular challenges in terms of development and clinical and commercial deployment. Despite multiple FDA approvals, challenges in global access, manufacturing and targeting complex diseases such as solid tumors remains challenging. This webinar will present a history of CAR-T therapy and outline recent and emerging innovations of these therapies in terms of disease targeting, CAR design and architecture, and manufacturing advancements.

 

Speaker:

Sandro Matosevic, Ph.D.

Dr. Sandro Matosevic is an assistant professor in the College of Pharmacy at Purdue University, and is a member of the Purdue Center for Cancer Research. Dr. Matosevic runs an NIH-funded research program focused on the development and use of cell-based therapies with natural killer cells and CAR-engineered immune cells in the treatment of cancer and holds a number of patents on the engineering and utilization of NK cells and stem cell-derived NK cells in cancer immunotherapy.

Dr. Matosevic is on the editorial board of several journals, acts on pharmaceutical advisory boards, and has been on committees for several organizations advancing the development and standardization of cell-based therapies, and is current chair of the BIO Focus group of the National Institute for Pharmaceutical Technology and Education. Dr. Matosevic obtained his graduate degree from University College London and completed his postdoctoral training at the Scripps Research Institute.

No comments:

Post a Comment

FDA and CMS issue statement on LDTs: Americans Deserve Accurate and Reliable Diagnostic Tests, Wherever They Are Made

This joint statement notes the evolution of Laboratory Developed Tests (LDTs) from the initial rule and approach the FDA had for oversite, a...